OP0196 Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study. (12th June 2018)

• Record Type: Journal Article
• Authors: Tison, A.; Quere, G.; Misery, L.; Funck-Brentano, E.; Danlos, F.-X.; Bonniaud, B.; Scalbert, C.; Lesimple, T.; Martinez, S.; Marcq, M.; Chouaid, C.; Dubos, C.; Brunet-Possenti, F.; Stavris, C.; Chiche, L.Y.; Cornec, D.; Kostine, M.; Français de, Pneumo-Cancérologie (GFPC) Groupe; et Inflammation (CRI), Club Rhumatisme
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 147
• Page End: 147
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.5840
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Immune Checkpoint Inhibitors (ICI) have revolutionised the management of several cancers, enhancing the anti-tumoral immune response. However they are responsible for many Immune Related Adverse Effects (IRAE), and therefore most patients with Preexisting Autoimmune Diseases (PAD) have been excluded from clinical trials. Objectives: The aim of this study was to evaluate the safety and efficacy of ICI in patients with PAD. Methods: Three national expert networks, focusing respectively on skin cancers, thoracic cancers and inflammatory diseases participated in this study. All patients who received an ICI despite a PAD in clinical practice were included in this nationwide retrospective study. Results: 112 patients were included: 64 men (57.1%), median age 66.5. Most patients received an anti-PD1 or anti-PD-L1 drug (84.8%). Main cancer types were melanoma (n=66, 58.9%) and Non-Small Cell Lung Carcinoma (NSCLC) (n=40; 35.7%). Median follow-up was 8 months [0–52]. Most frequent PAD were psoriasis and psoriatic arthritis (27.6%), rheumatoid arthritis (17.8%), inflammatory bowel disease (12.5%), spondyloarthritis (4.5%), lupus (6.3%), polymyalgia rheumatica and/or giant-cell arteritis (6.3%). 24 patients (21.6%) were receiving an immunosuppressive therapy (IS) at ICI initiation (including steroids in 15, sDMARD in 10 and rituximab in 1). 37 patients (33%) had an active disease. PAD flares were frequent (n=47; 42%) and 30.4% of them were severe (grade CTCAE 3–4). 26 patients (56.5%) received an IS treatment for a flare (22 received steroids and 7 a DMARD). Other IRAEs not related to the PAD occurred in 43 patients (38.4%), 41.5% were severe. 23 patients (56.1%) required an IS (including a DMARD in 4). 36 patients (32.1%) discontinued ICI temporarily or definitively because of a flare or an IRAE. One patient died due to an IRAE. Concerning the anti-tumoral response, the Overall Response Rate (ORR) was 48.3% for melanoma and 53.8% for NSCLC. The median Progression Free Survival (PFS) was 12.4 months for melanoma and 9.7 for NSCLC. Median overall survival (OS) was not reached in any group. PFS and OS were shorter in patients receiving an IS treatment at ICI initiation (p=0.007, figure 1A, and p=0.003, respectively). PFS and OS were longer in patients who experienced a PAD flare or other IRAE, but this gain was lost when an IS was used to treat the flare/IRAE (p=0.008, figure 1B, and p=0.01, respectively). Conversely, this gain was not impacted with ICI discontinuation. Conclusions: PAD flares and other IRAEs are frequent during ICI therapy and may be severe. The OS, ORR and PFS seem high in patients with PAD. The occurrence of a flare/IRAE is associated to a better outcome, gain lost when IS are used, while ICI discontinuation has no impact on PFS. Further prospective studies are needed to confirm our findings. Disclosure of Interest: None declared